Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. “I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”
To view the full press release, visit https://ibn.fm/dao0s
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey Health is a medical company focused on developing life enhancing medical solutions. Odyssey’s corporate mission is to develop and commercialize exceptional technologies that provide meaningful medical solutions. The company is focused on technologies that provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. For more information, visit the company’s website at www.OdysseyHealthInc.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
